Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.56 |
| ▸ | INSR | P06213 | 8/20 | 0.56 |
| ▸ | IGF1R | P08069 | 8/20 | 0.56 |
| ▸ | EGFR | P00533 | 5/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.49 |
| ▸ | STK10 | O94804 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | CD74 | P04233 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620223 | 1.00 | ALK (0.56) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620190 | 0.92 | ALK (0.59) | ALKEGFRPTK2 | |
| SCHEMBL29791364 | 0.91 | ALK (0.67) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620284 | 0.91 | ALK (0.67) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL29791447 | 0.90 | ALK (0.61) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620272 | 0.90 | ALK (0.61) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL29791371 | 0.89 | ALK (0.59) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620279 | 0.89 | ALK (0.59) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620155 | 0.89 | EGFR (0.51) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL30833021 | 0.89 | EGFR (0.51) | ALKINSRIGF1REGFRMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | ALK 430/4885INSR 1031/4885IGF1R 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.